Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain
Authors Sánchez-Cenizo L, Aller J, Martínez-Sesmero JM, Mir N, Peral C, Rubio-Rodríguez D, Rubio-Terrés C
Received 5 February 2019
Accepted for publication 25 June 2019
Published 22 July 2019 Volume 2019:11 Pages 465—475
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Giorgio Lorenzo Colombo
Laura Sánchez-Cenizo,1 Javier Aller,2 José Manuel Martínez-Sesmero,3 Nuria Mir,1 Carmen Peral,1 Darío Rubio-Rodríguez,4 Carlos Rubio-Terrés4
1Medical Department, Pfizer, S.L.U, Madrid, Spain; 2Endocronology Department, Hospital Universitario Puerta De Hierro, Majadahonda, Madrid, Spain; 3Hospital Pharmacy Department, Hospital Clinico San Carlos, Madrid, Spain; 4Pharmacoeconomics Department, Health Value, Madrid, Spain
Objective: To evaluate the burden of diabetes mellitus (DM) in adult patients with acromegaly treated with second-line pharmacotherapy, from the perspective of the Spanish National Health System (NHS).
Methods: A Markov model was developed including three states: normal glucose metabolism, DM and death. The evolution of a hypothetical cohort of acromegaly patients requiring second-line pharmacological treatment (pegvisomant or pasireotide) after first generation somatostatin analogues therapy was analyzed. Direct healthcare costs regarding acromegaly management, diabetes management and drugs costs were obtained from Spanish sources. Transition probabilities between health states were obtained from published studies. Deterministic and probabilistic sensitivity analyses were undertaken.
Results: Compared to pasireotide, pegvisomant increased the likelihood of glucose normalization and reduced the likelihood of DM. Consequently, in a cohort of 1,000 patients with acromegaly, treatment with pegvisomant compared to pasireotide would prevent 243, 413 and 453 cases of DM after 1, 2 and 5 years, respectively, and would reduce mortality by 0.1% after 5 years of treatment. This would result in 1 million euros savings for the NHS in 5 years. These health benefits would be obtained with savings of €1,512, €3,422 and €10,162 per patient treated with pegvisomant, after 1, 2 and 5 years, respectively. After 5 years of treatment, the probability that pegvisomant generated savings versus pasireotide would be 65.3%.
Conclusion: The favorable effects of pegvisomant on glucose metabolism would allow a considerable number of cases of DM to be avoided compared to pasireotide, resulting in savings for the NHS in Spain.
Keywords: diabetes mellitus, acromegaly, burden of illness, pegvisomant, pasireotide
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]